phrykt

Curanex Pharmaceuticals Inc (CURX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of CURX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No CURX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CURX short interest

Low short interest. Less than 0.1% of CURX shares are sold short. Over the last 12 reports the number of shares short went down 84%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5,945 CURX shares were sold short, 0.0% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 13,269 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.02%May 15Oct 300.15%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265,9450.02%+14%13,2691.0
Oct 15, 20265,1950.02%+68%28,1961.0
Sep 30, 20263,0840.01%+9%16,5601.0
Sep 15, 20262,8230.01%+529%31,6371.0
Aug 31, 20264490.00%-98%35,0241.0
Aug 14, 202624,3750.08%+97%152,8011.0
Jul 31, 202612,3890.04%+5%67,6771.0
Jul 15, 202611,8290.04%-43%81,3381.0
Jun 30, 202620,8350.07%-38%77,0011.0
Jun 15, 202633,6100.12%+32%94,8191.0
May 29, 202625,4390.09%-32%56,2191.0
May 15, 202637,2510.13%-22%145,2951.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Curanex Pharmaceuticals company events

Curanex Pharmaceuticals filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 19, 2026.

  1. Oct 19, 2026AnnouncementDaymond Morales, et al., filed a putative securities class action in the Supreme Court of the State of New York, New York County (Index No. 159271/2026), against the Company and its underwriters Dominari Securities LLC, Pacific Century Securities, LLC, and Revere Securities LLC, as well as more… Filing
  2. Sep 4, 2026AnnouncementAs previously disclosed by Curanex Pharmaceuticals Inc, on November 5, 2025, the Company was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC that the Company failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required… Filing
  3. Aug 17, 2026SharesChanged the rights of its shareholders. Filing
  4. May 14, 2026AnnouncementShared information with investors. Filing
  5. May 7, 2026AnnouncementAs previously reported by Curanex Pharmaceuticals Inc, on November 5, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that for the last 30 consecutive business days the closing bid price for its common stock was… Filing
  6. Apr 2, 2026AnnouncementShared information with investors. Filing
  7. Mar 6, 2026LeadershipWith respect to the Employment Agreement with Jun Liu and the Employment Agreement with Dr. Liqin Xie is incorporated by reference into this Item 1.01. Filing
  8. Jan 5, 2026LeadershipHaiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Curanex Pharmaceuticals financials

Famous investors that hold CURX

1 of the 50 well-known investors we track reported holding CURX in their latest 13F filing. The largest position is Ken Griffin's, worth $61.9K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202612,255$61.9K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Curanex Pharmaceuticals Inc (CURX) stock

Are CURX insiders buying or selling?

No CURX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in CURX?

As of Oct 30, 2026, 5,945 CURX shares were sold short, 0.0% of the shares outstanding, up 14.4% from the report before. At the average daily volume of 13,269 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold CURX?

1 of the 50 well-known investors we track reported CURX in their latest 13F filing, including Ken Griffin. The largest position is worth $61.9K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.